

3) Moreover, nationwide lockdowns forced manufacturing facilities to partially or completely shut their operations.

4) Adverse impacts of the COVID-19 pandemic have resulted in delays in activities and initiatives regarding development of reliable and innovative drone analytics systems globally.

Based on type, the targeted therapy segment held the largest share in 2020, accounting for more than half of the market. However, the immunotherapy segment is projected to manifest the highest CAGR of 8.7% during the forecast period.

On the basis of bases, the breast cancer segment held the lion's share in 2020, contributing to nearly one-fifth of the market. However, the lung cancer segment is estimated to portray the highest CAGR of 9.3% from 2021 to 2030.

□□□ □□□□□□□□ □□□□□-□□ □□□□□□ □□□□□□□□ □□: <https://www.alliedmarketresearch.com/request-for-customization/121?reqfor=covid>

□ □□□ □□□□□□□□ □□ □□□□□□□□□□□□

- This report entails a detailed quantitative analysis along with the current global Oncology/Cancer Drugs Market trends from 2021 to 2030 to identify the prevailing opportunities along with the strategic assessment.
- The Oncology/Cancer Drugs Market forecast is studied from 2021 to 2030.
- The Oncology/Cancer Drugs Market size and estimations are based on a comprehensive analysis of key developments in the endoscopic retrograde cholangiopancreatography industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the Oncology/Cancer Drugs Market.

□□□ □□□□□ □□□ □□□□□□□□ □□□:

- AbbVie Inc.
- Amgen
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson (Janssen Global Services, LLC,)

David Correa
Allied Analytics LLP
+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/559267593>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.